668477-94-9

Basic information

• Product Name: (4-METHYL-2-[3-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOL-5-YL)METHANOL
• Synonyms: (4-METHYL-2-[3-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOL-5-YL)METHANOL;5-(Hydroxymethyl)-4-methyl-2-[3-(trifluoromethyl)phenyl]-1,3-thiazole
• CAS NO: 668477-94-9
• Molecular Formula: C₁₂H₁₀F₃NOS
• Molecular Weight: 273.27
• Mol File: 668477-94-9.mol
• Article Data: 5

Chemical Properties

• Melting Point: 50-52°C
• Appearance: /
• CAS DataBase Reference: (4-METHYL-2-[3-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOL-5-YL)METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (4-METHYL-2-[3-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOL-5-YL)METHANOL(668477-94-9)
• EPA Substance Registry System: (4-METHYL-2-[3-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOL-5-YL)METHANOL(668477-94-9)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 668477-94-9(Hazardous Substances Data)

Usage

Description

(4-METHYL-2-[3-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOL-5-YL)METHANOL is a chemical compound with the formula C12H10F3NOS. It is a thiazole derivative with a trifluoromethyl group attached to the phenyl ring. The presence of the methyl and trifluoromethyl groups gives this compound its unique chemical properties. It is commonly used in the pharmaceutical industry as a building block for the synthesis of various pharmaceutical products. (4-METHYL-2-[3-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOL-5-YL)METHANOL has also been studied for its potential biological activities, including its anti-inflammatory and anti-cancer properties. Overall, (4-METHYL-2-[3-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOL-5-YL)METHANOL is a versatile compound with potential applications in various fields, particularly in medicinal chemistry and drug development.
Used in Pharmaceutical Industry:
(4-METHYL-2-[3-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOL-5-YL)METHANOL is used as a building block for the synthesis of various pharmaceutical products due to its unique chemical properties.
Used in Medicinal Chemistry:
(4-METHYL-2-[3-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOL-5-YL)METHANOL is used as a compound with potential biological activities, including its anti-inflammatory and anti-cancer properties, for the development of new drugs and therapies.
Used in Drug Development:
(4-METHYL-2-[3-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOL-5-YL)METHANOL is used as a versatile compound for the development of new drugs and therapies, particularly in the field of medicinal chemistry.

Upstream product

• 144061-14-3 4-methyl-2-[3-(trifluoromethyl)phenyl]thiazole-5-carboxylic acid ethyl ester 
• 1801-10-1 3-trifluoromethylbenzamide 
• 53515-17-6 3-(trifluoromethyl)benzothioamide 

Downstream Products

• 1219625-78-1 5-(bromomethyl)-4-methyl-2-(3-(trifluoromethyl)phenyl)thiazole 

Relevant articles and documents

Synthesis and Evaluation of PPARδAgonists That Promote Osteogenesis in a Human Mesenchymal Stem Cell Culture and in a Mouse Model of Human Osteoporosis

We synthesized a directed library of compounds to explore the structure-activity relationships of peroxisome proliferator-activated receptor δ(PPARδ) activation relative to mesenchymal stem cell (MSC) osteogenesis. Our scaffold used para-substituted cinnamic acids as a polar headgroup, a heteroatom and heterocycle core connecting units, and substituted phenyl groups for the lipophilic tail. Compounds were screened for their ability to increase osteogenesis in MSCs, and the most promising were examined for subunit specificity using a quantitative PPAR transactivation assay. Six compounds were selected for in vivo studies in an ovariectomized mouse model of human postmenopausal osteoporosis. Four compounds improved bone density in vivo, with two (12d and 31a) having activity comparable to that of GW0742, a well-studied PPARδ-selective agonist. 31a (2-methyl-4-[N-methyl-N-[5-methylene-4-methyl-2-[4-(trifluoromethyl)phenyl]thiazole]]aminocinnamic acid) had the highest selectivity for PPARδcompared to other subtypes, its selectivity far exceeding that of GW0742. Our results confirm that PPARδis a new drug target for possible treatment of osteoporosis via in situ manipulation of MSCs.

HETEROCYCLIC DERIVATIVE AND USE THEREOF

The present invention aims to provide a compound having superior pharmacological action, physicochemical properties and the like and useful as an sGC activation drug, or an agent for the prophylaxis and/or treatment of diseases such as hypertension, ischemic cardiac disease, cardiac failure, kidney disease, arteriosclerotic disease, atrial fibrillation, pulmonary hypertension, diabetes, diabetic complications, metabolic syndrome, peripheral arterial obstruction, erectile dysfunction and the like. An sGC activation drug containing a compound represented by the formula (II): wherein each symbol is as defined in the specification, or a salt thereof, as an active ingredient.

NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS

The present invention relates to compounds of formula (I) wherein Rl to R10, X, Y and n are as defined in the description and claims, and pharmaceutically acceptable salts and esters thereof. The compounds are useful for the treatment of diseases such as diabetes.